Rapid Turnover of Extracellular Signal-Regulated Kinase 3 by the Ubiquitin-Proteasome Pathway Defines a Novel Paradigm of Mitogen-Activated Protein Kinase Regulation during Cellular Differentiation

REFERENCES

• Blau, H. M., G. K. Pavlath, E. C. Hardeman, C. P. Chiu, L. Silberstein, S. G. Webster, S. C. Miller, and C. Webster. 1985. Plasticity of the differentiated state. Science 230: 758–766.
   PubMed Web of Science ®Google Scholar
• Boulton, T. G., S. H. Nye, D. J. Robbins, N. Y. Ip, E. Radziejewska, S. D. Morgenbesser, R. A. DePinho, N. Panayotatos, M. H. Cobb, and G. D. Yancopoulos. 1991. ERKs: a family of protein-serine/threonine kinases that are activated and tyrosine phosphorylated in response to insulin and NGF. Cell 65: 663–675.
   PubMed Web of Science ®Google Scholar
• Brunet, A., D. Roux, P. Lenormand, S. Dowd, S. Keyse, and J. Pouyssegur. 1999. Nuclear translocation of p42/p44 mitogen-activated protein kinase is required for growth factor-induced gene expression and cell cycle entry. EMBO J. 18: 664–674.
   PubMed Web of Science ®Google Scholar
• Chang, L., and M. Karin. 2001. Mammalian MAP kinase signalling cascades. Nature 410: 37–40.
   PubMed Web of Science ®Google Scholar
• Cheng, M., T. G. Boulton, and M. H. Cobb. 1996. ERK3 is a constitutively nuclear protein kinase. J. Biol. Chem. 271: 8951–8958.
   PubMed Web of Science ®Google Scholar
• Chowdary, D. R., J. J. Dermody, K. K. Jha, and H. L. Ozer. 1994. Accumulation of p53 in a mutant cell line defective in the ubiquitin pathway. Mol. Cell. Biol. 14: 1997–2003.
   PubMed Web of Science ®Google Scholar
• Coulombe, P., and S. Meloche. 2002. Dual-tag prokaryotic vectors for enhanced expression of full-length recombinant proteins. Anal. Biochem. 310: 219–222.
   PubMedGoogle Scholar
• English, J., G. Pearson, J. Wilsbacher, J. Swantek, M. Karandikar, S. Xu, and M. H. Cobb. 1999. New insights into the control of MAP kinase pathways. Exp. Cell Res. 253: 255–270.
   PubMed Web of Science ®Google Scholar
• Fenteany, G., R. F. Standaert, W. S. Lane, S. Choi, E. J. Corey, and S. L. Schreiber. 1995. Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin. Science 268: 726–731.
   PubMed Web of Science ®Google Scholar
• Glickman, M. H., and A. Ciechanover. 2002. The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol. Rev. 82: 373–428.
   PubMed Web of Science ®Google Scholar
• Goodfellow, P. J. 1994. Inherited cancers associated with the RET proto-oncogene. Curr. Opin. Genet. Dev. 4: 446–452.
   PubMedGoogle Scholar
• Greene, L. A., and A. S. Tischler. 1976. Establishment of a noradrenergic clonal line of rat adrenal pheochromocytoma cells which respond to nerve growth factor. Proc. Natl. Acad. Sci. USA 73: 2424–2428.
   PubMed Web of Science ®Google Scholar
• Guan, K. L., and J. E. Dixon. 1991. Eukaryotic proteins expressed in Escherichia coli: an improved thrombin cleavage and purification procedure of fusion proteins with glutathione S-transferase. Anal. Biochem. 192: 262–267.
   PubMed Web of Science ®Google Scholar
• Guex, N., and M. C. Peitsch. 1997. SWISS-MODEL and the Swiss-PdbViewer: an environment for comparative protein modeling. Electrophoresis 18: 2714–2723.
   PubMed Web of Science ®Google Scholar
• Halevy, O., B. G. Novitch, D. B. Spicer, S. X. Skapek, J. Rhee, G. J. Hannon, D. Beach, and A. B. Lassar. 1995. Correlation of terminal cell cycle arrest of skeletal muscle with induction of p21 by MyoD. Science 267: 1018–1021.
   PubMed Web of Science ®Google Scholar
• Harris, K. F., I. Shoji, E. M. Cooper, S. Kumar, H. Oda, and P. M. Howley. 1999. Ubiquitin-mediated degradation of active Src tyrosine kinase. Proc. Natl. Acad. Sci. USA 96: 13738–13743.
   PubMed Web of Science ®Google Scholar
• Hershko, A., and A. Ciechanover. 1998. The ubiquitin system. Annu. Rev. Biochem. 67: 425–479.
   PubMed Web of Science ®Google Scholar
• Hochstrasser, M. 1996. Ubiquitin-dependent protein degradation. Annu. Rev. Genet. 30: 405–439.
   PubMed Web of Science ®Google Scholar
• Kahn, C. R., D. Vicent, and A. Doria. 1996. Genetics of non-insulin-dependent (type-II) diabetes mellitus. Annu. Rev. Med. 47: 509–531.
   PubMed Web of Science ®Google Scholar
• Lee, H. W., L. Smith, G. R. Pettit, A. Vinitsky, and J. B. Smith. 1996. Ubiquitination of protein kinase C-alpha and degradation by the proteasome. J. Biol. Chem. 271: 20973–20976.
   PubMed Web of Science ®Google Scholar
• Lee, J. C., S. Kumar, D. E. Griswold, D. C. Underwood, B. J. Votta, and J. L. Adams. 2000. Inhibition of p38 MAP kinase as a therapeutic strategy. Immunopharmacology 47: 185–201.
   PubMed Web of Science ®Google Scholar
• Levitzki, A. 1999. Protein tyrosine kinase inhibitors as novel therapeutic agents. Pharmacol. Ther. 82: 231–239.
   PubMed Web of Science ®Google Scholar
• Lewis, T. S., P. S. Shapiro, and N. G. Ahn. 1998. Signal transduction through MAP kinase cascades. Adv. Cancer Res. 74: 49–139.
   PubMed Web of Science ®Google Scholar
• Lu, Z., S. Xu, C. Joazeiro, M. H. Cobb, and T. Hunter. 2002. The PHD domain of MEKK1 acts as an E3 ubiquitin ligase and mediates ubiquitination and degradation of ERK1/2. Mol. Cell 9: 945–956.
   PubMed Web of Science ®Google Scholar
• Marshall, C. J. 1995. Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation. Cell 80: 179–185.
   PubMed Web of Science ®Google Scholar
• Mayer, R. J. 2000. The meteoric rise of regulated intracellular proteolysis. Nat. Rev. Mol. Cell. Biol. 1: 145–148.
   PubMedGoogle Scholar
• Meloche, S., B. G. Beatty, and J. Pellerin. 1996. Primary structure, expression and chromosomal locus of a human homolog of rat ERK3. Oncogene 13: 1575–1579.
   PubMedGoogle Scholar
• Meloche, S., G. Pages, and J. Pouyssegur. 1992. Functional expression and growth factor activation of an epitope-tagged p44 mitogen-activated protein kinase, p44mapk. Mol. Biol. Cell 3: 63–71.
   PubMedGoogle Scholar
• Meloche, S., K. Seuwen, G. Pages, and J. Pouyssegur. 1992. Biphasic and synergistic activation of p44MAPK (ERK1) by growth factors: correlation between late phase activation and mitogenicity. Mol. Endocrinol. 6: 845–854.
   PubMed Web of Science ®Google Scholar
• Morgenstern, J. P., and H. Land. 1990. Advanced mammalian gene transfer: high titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line. Nucleic Acids Res. 18: 3587–3596.
   PubMed Web of Science ®Google Scholar
• Mori, S., C. H. Heldin, and L. Claesson-Welsh. 1992. Ligand-induced polyubiquitination of the platelet-derived growth factor beta-receptor. J. Biol. Chem. 267: 6429–6434.
   PubMedGoogle Scholar
• Murakami, Y., S. Matsufuji, T. Kameji, S. Hayashi, K. Igarashi, T. Tamura, K. Tanaka, and A. Ichihara. 1992. Ornithine decarboxylase is degraded by the 26S proteasome without ubiquitination. Nature 360: 597–599.
   PubMed Web of Science ®Google Scholar
• Oren, M. 1999. Regulation of the p53 tumor suppressor protein. J. Biol. Chem. 274: 36031–36034.
   PubMed Web of Science ®Google Scholar
• Pagano, M., S. W. Tam, A. M. Theodoras, P. Beer-Romero, G. Del Sal, V. Chau, P. R. Yew, G. F. Draetta, and M. Rolfe. 1995. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 269: 682–685.
   PubMed Web of Science ®Google Scholar
• Palombella, V. J., O. J. Rando, A. L. Goldberg, and T. Maniatis. 1994. The ubiquitin-proteasome pathway is required for processing the NF-κB1 precursor protein and the activation of NF-κB. Cell 78: 773–785.
   PubMed Web of Science ®Google Scholar
• Parker, S. B., G. Eichele, P. Zhang, A. Rawls, A. T. Sands, A. Bradley, E. N. Olson, J. W. Harper, and S. J. Elledge. 1995. p53-independent expression of p21Cip1 in muscle and other terminally differentiating cells. Science 267: 1024–1027.
   PubMed Web of Science ®Google Scholar
• Payne, D. M., A. J. Rossomando, P. Martino, A. K. Erickson, J. H. Her, J. Shabanowitz, D. F. Hunt, M. J. Weber, and T. W. Sturgill. 1991. Identification of the regulatory phosphorylation sites in pp42/mitogen-activated protein kinase (MAP kinase). EMBO J. 10: 885–892.
   PubMed Web of Science ®Google Scholar
• Pearson, G., F. Robinson, G. T. Beers, B. E. Xu, M. Karandikar, K. Berman, and M. H. Cobb. 2001. Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocrinol. Rev. 22: 153–183.
   PubMed Web of Science ®Google Scholar
• Peitsch, M. C. 1996. ProMod and Swiss-Model: internet-based tools for automated comparative protein modeling. Biochem. Soc. Trans. 24: 274–279.
   PubMed Web of Science ®Google Scholar
• Pelletier, J., and N. Sonenberg. 1988. Internal initiation of translation of eukaryotic mRNA directed by a sequence derived from poliovirus RNA. Nature 334: 320–325.
   PubMed Web of Science ®Google Scholar
• Penela, P., A. Ruiz-Gomez, J. G. Castano, and F. Mayor, Jr. 1998. Degradation of the G protein-coupled receptor kinase 2 by the proteasome pathway. J. Biol. Chem. 273: 35238–35244.
   PubMed Web of Science ®Google Scholar
• Polyak, K., M. H. Lee, H. Erdjument-Bromage, A. Koff, J. M. Roberts, P. Tempst, and J. Massague. 1994. Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 78: 59–66.
   PubMed Web of Science ®Google Scholar
• Robinson, M. J., S. A. Stippec, E. Goldsmith, M. A. White, and M. H. Cobb. 1998. A constitutively active and nuclear form of the MAP kinase ERK2 is sufficient for neurite outgrowth and cell transformation. Curr. Biol. 8: 1141–1150.
   PubMed Web of Science ®Google Scholar
• Robinson, M. J., B. E. Xu Be, S. Stippec, and M. H. Cobb. 2002. Different domains of the mitogen-activated protein kinases ERK3 and ERK2 direct subcellular localization and upstream specificity in vivo. J. Biol. Chem. 277: 5094–5100.
   PubMedGoogle Scholar
• Rock, K. L., C. Gramm, L. Rothstein, K. Clark, R. Stein, L. Dick, D. Hwang, and A. L. Goldberg. 1994. Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. Cell 78: 761–771.
   PubMed Web of Science ®Google Scholar
• Rodier, G., A. Montagnoli, L. Di Marcotullio, P. Coulombe, G. F. Draetta, M. Pagano, and S. Meloche. 2001. p27 cytoplasmic localization is regulated by phosphorylation on Ser10 and is not a prerequisite for its proteolysis. EMBO J. 20: 6672–6682.
   PubMed Web of Science ®Google Scholar
• Schaeffer, H. J., and M. J. Weber. 1999. Mitogen-activated protein kinases: specific messages from ubiquitous messengers. Mol. Cell. Biol. 19: 2435–2444.
   PubMed Web of Science ®Google Scholar
• Semenza, G. L. 2001. HIF-1, O(2), and the 3 PHDs: how animal cells signal hypoxia to the nucleus. Cell 107: 1–3.
   PubMed Web of Science ®Google Scholar
• Servant, M. J., P. Coulombe, B. Turgeon, and S. Meloche. 2000. Differential regulation of p27Kip1 expression by mitogenic and hypertrophic factors: involvement of transcriptional and posttranscriptional mechanisms. J. Cell Biol. 148: 543–556.
   PubMed Web of Science ®Google Scholar
• Sheaff, R. J., J. D. Singer, J. Swanger, M. Smitherman, J. M. Roberts, and B. E. Clurman. 2000. Proteasomal turnover of p21Cip1 does not require p21Cip1 ubiquitination. Mol. Cell 5: 403–410.
   PubMed Web of Science ®Google Scholar
• Treier, M., L. M. Staszewski, and D. Bohmann. 1994. Ubiquitin-dependent c-Jun degradation in vivo is mediated by the delta domain. Cell 78: 787–798.
   PubMed Web of Science ®Google Scholar
• Turgeon, B., M. K. Saba-El-Leil, and S. Meloche. 2000. Cloning and characterization of mouse extracellular-signal-regulated protein kinase 3 as a unique gene product of 100 kDa. Biochem. J. 346(Pt. 1): 169–175.
   PubMedGoogle Scholar
• Webster, M. K., and D. J. Donoghue. 1997. FGFR activation in skeletal disorders: too much of a good thing. Trends Genet. 13: 178–182.
   PubMed Web of Science ®Google Scholar
• Weston, C. R., and R. J. Davis. 2002. The JNK signal transduction pathway. Curr. Opin. Genet. Dev. 12: 14–21.
   PubMed Web of Science ®Google Scholar
• Widmann, C., S. Gibson, M. B. Jarpe, and G. L. Johnson. 1999. Mitogen-activated protein kinase: conservation of a three-kinase module from yeast to human. Physiol. Rev. 79: 143–180.
   PubMed Web of Science ®Google Scholar
• Zhang, F., A. Strand, D. Robbins, M. H. Cobb, and E. J. Goldsmith. 1994. Atomic structure of the MAP kinase ERK2 at 2.3 Å resolution. Nature 367: 704–711.
   Google Scholar
• Zhu, A. X., Y. Zhao, D. E. Moller, and J. S. Flier. 1994. Cloning and characterization of p97MAPK, a novel human homolog of rat ERK-3. Mol. Cell. Biol. 14: 8202–8211.
   PubMed Web of Science ®Google Scholar
• Zimmermann, J., N. Lamerant, R. Grossenbacher, and P. Furst. 2001. Proteasome- and p38-dependent regulation of ERK3 expression. J. Biol. Chem. 276: 10759–10766.
   PubMedGoogle Scholar